INFO & CONTACTS:  +39 02 2390 1

A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Phase: Phase III clinical trials

Principal Investigator: Dott.ssa Verzoni Elena

Main Facility: Oncologia Medica Genitourinaria

Drug: Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients

Pathologies: Urological cancers (kidney, bladder, urinary tract, others)

This is a Phase 3, randomized, active-control, placebo-controlled, double-blind, 2-arm, global, multicenter study to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic ccRCC who have experienced progression on or after prior anti-PD-1 or antiPD-L1 immunotherapy

Last update: 09/06/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe